Pulmonary Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1066039
  • May 2021
  • Pharmaceuticals
  • 133 Pages
The Pulmonary Drugs market research report provides an in-depth analysis of the currents trends, latest developments, scenario, market size, various drivers, restraints, and major players along with their profile details. Research report offers the historic data for year 2018 and 2019 and also provides the forecast data from year 2020 to 2028 which is based on revenue (USD Million). With the help of all these information research report helps the market participants to improve market positions. With the help of all these insights Pulmonary Drugs market research report recommends a business strategy for present market participants to strengthen their position in the market.
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered Sanofi, Mylan N.V., Circassia, AstraZeneca Plc., GlaxoSmithKline Plc, Mallinckrodt, CHIESI Farmaceutici SpA, ZAMBON COMPANY S.P.A., Alaxia, Merck KGaA
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Impact Analysis
The analysis of covid-19 is based on the impact of the current pandemic situation on market scenarios. This includes impact of covid-19 outbreak on overall revenue, market segments as well as regional market. The report also puts light on detailed impact analysis by taking into consideration all the government policies imposed during the pandemic situation, temporary shutdown of manufacturing units, current state of supply chain and distributors, and its future impacts on the growth of overall market. The market study will assist user to understand the global demand and impose strategic business plans to compete with the peers.

Furthermore, the research report includes the detailed information about major players and provides the data regarding the current market scenario as well as upcoming market opportunities or challenges. Similarly, in segment report covers the types, and applications according to the countries and key regions. The research report consists the various drivers and restraints for Pulmonary Drugs market along with their effects over the forecast period. Similarly, according to the region Pulmonary Drugs market research report includes the study of opportunities available in the market situation.

The Pulmonary Drugs market research report provides the in-depth data analysis by using the various graphs, figures, charts, and tables. Furthermore, the report provides the different business challenges which are impacting market growth in all direction.

Major Key Players for Global Pulmonary Drugs Market:
The Pulmonary Drugs market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. Sanofi, Mylan N.V., Circassia, AstraZeneca Plc., GlaxoSmithKline Plc, Mallinckrodt, CHIESI Farmaceutici SpA, ZAMBON COMPANY S.P.A., Alaxia, Merck KGaA

Pulmonary Drugs Market Segmentation Analysis:
by Drug Class
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Short Acting Beta-2 Agonists
Others
Application
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Pulmonary Drugs Market Segmentation by Regions:
In regional analysis, Pulmonary Drugs market research report provides the detailed analysis from various regions and also contains the detailed analysis of country. Along with market revenue, market value report also offers the forecast analysis for the following countries and regions. Global Pulmonary Drugs market report covers the various geographical regions such as North America, Asia-Pacific, Europe, Latin America, and Middle East & Africa. Also, various countries included are Canada, U.K., France, the U.S., Japan, China, India, and Germany and so on.

North America Region for Pulmonary Drugs Market: Value and Forecast
  • U.S.
  • Canada
 Europe Region for Pulmonary Drugs Market: Value and Forecast
  • UK
  • Germany
  • France
  • Rest of the Europe
 Asia Pacific Region for Pulmonary Drugs Market: Value and Forecast
  • China
  • Japan
  • India
  • Rest of the Asia Pacific
 Latin America Region for Pulmonary Drugs Market: Value and Forecast
  • Mexico
  • Brazil
  • Rest of the Latin America
 Middle East and Africa for Pulmonary Drugs Market: Value and Forecast
  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa


Important Points Covered by Report:
  • To analyze the value of the Pulmonary Drugs market, according to the key region.
  • To study the Pulmonary Drugs market current trends, prospects and also their participation in the entire sector.
  • Report consists the in-depth information related to the region/countries, major key players, current trends and their analysis, product type, applications, and other background information
  • Report provides the detailed information about drivers, restraints and future scope of Pulmonary Drugs market.
  • Report covers the information about historic data analysis as well as forecast period analysis.

Global Pulmonary Drugs research report consist the information about overall sales and revenue during the historic and forecasted period of 2018 to 2028. Additionally, this report covers the inside and out factual examination and the market elements and requests which give an entire situation of the business.

Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the Pulmonary Drugs market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the Pulmonary Drugs market for numerous purposes such as:

    1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the Pulmonary Drugs market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the Pulmonary Drugs market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the Pulmonary Drugs market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • Sanofi
  • Mylan N.V.
  • Circassia
  • AstraZeneca Plc.
  • GlaxoSmithKline Plc
  • Mallinckrodt
  • CHIESI Farmaceutici SpA
  • ZAMBON COMPANY S.P.A.
  • Alaxia
  • Merck KGaA
  • Inhaled Corticosteroids
  • Long Acting Beta-2 Agonists
  • Antihistamines
  • Vasodilators
  • Short Acting Beta-2 Agonists
  • Others
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global Pulmonary Drugs Market Snapshot
          2.1.1. Global Pulmonary Drugs Market By Drug Class,2019
               2.1.1.1.Inhaled Corticosteroids
               2.1.1.2.Long Acting Beta-2 Agonists
               2.1.1.3.Antihistamines
               2.1.1.4.Vasodilators
               2.1.1.5.Short Acting Beta-2 Agonists
               2.1.1.6.Others
          2.1.2. Global Pulmonary Drugs Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacies
               2.1.2.2.Retail Pharmacies
               2.1.2.3.Online Pharmacies
          2.1.3. Global Pulmonary Drugs Market By End-use,2019
          2.1.4. Global Pulmonary Drugs Market By Geography,2019

3. Global Pulmonary Drugs Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Drug Class, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Drug Class, 2020
     4.2. Global Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028

5. Global Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028

7. Global Pulmonary Drugs Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America Pulmonary Drugs Market Analysis, 2018 – 2028 
          7.2.1. North America Pulmonary Drugs Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028
          7.2.3. North America Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe Pulmonary Drugs Market Analysis, 2018 – 2028 
          7.3.1.  Europe Pulmonary Drugs Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028
          7.3.3. Europe Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific Pulmonary Drugs Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific Pulmonary Drugs Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028
          7.4.3. Asia Pacific Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America Pulmonary Drugs Market Analysis, 2018 – 2028 
          7.5.1.  Latin America Pulmonary Drugs Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028
          7.5.3. Latin America Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) Pulmonary Drugs Market Analysis, 2018 – 2028 
          7.6.1.  MEA Pulmonary Drugs Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA Pulmonary Drugs Market Size (US$), By Drug Class, 2018 – 2028
          7.6.3. MEA Pulmonary Drugs Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA Pulmonary Drugs Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key Pulmonary Drugs Providers
        8.4.1 Sanofi
                8.4.1.1 Business Description
                8.4.1.2 Sanofi Geographic Operations
                8.4.1.3 Sanofi Financial Information
                8.4.1.4 Sanofi Product Positions/Portfolio
                8.4.1.5 Sanofi Key Developments
        8.4.2 Mylan N.V.
                8.4.2.1 Business Description
                8.4.2.2 Mylan N.V. Geographic Operations
                8.4.2.3 Mylan N.V. Financial Information
                8.4.2.4 Mylan N.V. Product Positions/Portfolio
                8.4.2.5 Mylan N.V. Key Developments
        8.4.3 Circassia
                8.4.3.1 Business Description
                8.4.3.2 Circassia Geographic Operations
                8.4.3.3 Circassia Financial Information
                8.4.3.4 Circassia Product Positions/Portfolio
                8.4.3.5 Circassia Key Developments
        8.4.4 AstraZeneca Plc.
                8.4.4.1 Business Description
                8.4.4.2 AstraZeneca Plc. Geographic Operations
                8.4.4.3 AstraZeneca Plc. Financial Information
                8.4.4.4 AstraZeneca Plc. Product Positions/Portfolio
                8.4.4.5 AstraZeneca Plc. Key Developments
        8.4.5 GlaxoSmithKline Plc
                8.4.5.1 Business Description
                8.4.5.2 GlaxoSmithKline Plc Geographic Operations
                8.4.5.3 GlaxoSmithKline Plc Financial Information
                8.4.5.4 GlaxoSmithKline Plc Product Positions/Portfolio
                8.4.5.5 GlaxoSmithKline Plc Key Developments
        8.4.6 Mallinckrodt
                8.4.6.1 Business Description
                8.4.6.2 Mallinckrodt Geographic Operations
                8.4.6.3 Mallinckrodt Financial Information
                8.4.6.4 Mallinckrodt Product Positions/Portfolio
                8.4.6.5 Mallinckrodt Key Developments
        8.4.7 CHIESI Farmaceutici SpA
                8.4.7.1 Business Description
                8.4.7.2 CHIESI Farmaceutici SpA Geographic Operations
                8.4.7.3 CHIESI Farmaceutici SpA Financial Information
                8.4.7.4 CHIESI Farmaceutici SpA Product Positions/Portfolio
                8.4.7.5 CHIESI Farmaceutici SpA Key Developments
        8.4.8 ZAMBON COMPANY S.P.A.
                8.4.8.1 Business Description
                8.4.8.2 ZAMBON COMPANY S.P.A. Geographic Operations
                8.4.8.3 ZAMBON COMPANY S.P.A. Financial Information
                8.4.8.4 ZAMBON COMPANY S.P.A. Product Positions/Portfolio
                8.4.8.5 ZAMBON COMPANY S.P.A. Key Developments
        8.4.9 Alaxia
                8.4.9.1 Business Description
                8.4.9.2 Alaxia Geographic Operations
                8.4.9.3 Alaxia Financial Information
                8.4.9.4 Alaxia Product Positions/Portfolio
                8.4.9.5 Alaxia Key Developments
        8.4.10 Merck KGaA
                8.4.10.1 Business Description
                8.4.10.2 Merck KGaA Geographic Operations
                8.4.10.3 Merck KGaA Financial Information
                8.4.10.4 Merck KGaA Product Positions/Portfolio
                8.4.10.5 Merck KGaA Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global Pulmonary Drugs Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America Pulmonary Drugs Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 5 North America Pulmonary Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America Pulmonary Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe Pulmonary Drugs Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe Pulmonary Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe Pulmonary Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific Pulmonary Drugs Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific Pulmonary Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific Pulmonary Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America Pulmonary Drugs Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America Pulmonary Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America Pulmonary Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA Pulmonary Drugs Market Revenue, By Drug Class, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA Pulmonary Drugs Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA Pulmonary Drugs Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global Pulmonary Drugs: Market Segmentation 
FIG. 2 Global Pulmonary Drugs Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global Pulmonary Drugs Market, By Drug Class, 2019 (US$ Mn) 
FIG. 5 Global Pulmonary Drugs Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global Pulmonary Drugs Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global Pulmonary Drugs Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global Pulmonary Drugs Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key Pulmonary Drugs Providers, 2019
FIG. 11 Global Pulmonary Drugs Market Revenue Contribution, By Drug Class, 2019 & 2028 (Value %) 
FIG. 12 Global Pulmonary Drugs Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global Pulmonary Drugs Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America Pulmonary Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe Pulmonary Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific Pulmonary Drugs Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America Pulmonary Drugs Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA Pulmonary Drugs Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the Pulmonary Drugs market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global Pulmonary Drugs Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America Pulmonary Drugs Market Value, By Segment1, 2018 – 2028
TABLE  North America Pulmonary Drugs Market Value, By Segment2, 2018 – 2028
TABLE  North America Pulmonary Drugs Market Value, By Country, 2018 – 2028
TABLE  Europe Pulmonary Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Europe Pulmonary Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Europe Pulmonary Drugs Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific Pulmonary Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific Pulmonary Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific Pulmonary Drugs Market Value, By Country, 2018 – 2028
TABLE  Latin America Pulmonary Drugs Market Value, By Segment1, 2018 – 2028
TABLE  Latin America Pulmonary Drugs Market Value, By Segment2, 2018 – 2028
TABLE  Latin America Pulmonary Drugs Market Value, By Country, 2018 – 2028
TABLE  MEA Pulmonary Drugs Market Value, By Segment1, 2018 – 2028
TABLE  MEA Pulmonary Drugs Market Value, By Segment2, 2018 – 2028
TABLE  MEA Pulmonary Drugs Market Value, By Country, 2018 – 2028
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mylan N.V.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Circassia: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca Plc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  GlaxoSmithKline Plc: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Mallinckrodt: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  CHIESI Farmaceutici SpA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  ZAMBON COMPANY S.P.A.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Alaxia: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Merck KGaA: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global Pulmonary Drugs Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global Pulmonary Drugs Market, By Segment1, 2019 (US$ Mn)
FIG.  Global Pulmonary Drugs Market, By Segment2, 2019 (US$ Mn)
FIG.  Global Pulmonary Drugs Market, By Geography, 2019 (US$ Mn)
FIG.  Global Pulmonary Drugs Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key Pulmonary Drugs Providers, 2016
FIG.  Global Pulmonary Drugs Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Long Acting Beta-2 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Antihistamines Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Vasodilators Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Short Acting Beta-2 Agonists Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Pulmonary Drugs Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Retail Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Online Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  France Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  China Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  India Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA Pulmonary Drugs Market Value, 2018 – 2028, (US$ Mn)